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Summary
Antimicrobial stewardship (AMS) is an important compo-
nent in the fight against antimicrobial resistance. Currently,
few hospitals have an ongoing institutional AMS pro-
gramme. Swissnoso – the national centre for infection pre-
vention – has launched a national Swiss AMS initiative
supported by the office of public health. To guide AMS pri-
orities and resources, current AMS activities in Switzer-
land were assessed. We distributed an internet-based
questionnaire directed mainly to board-certified infectious
diseases specialists and, if not available, senior internal
medicine staff. Responses were received from 63/134
hospitals surveyed. More than 90% were in favour of na-
tional treatment guidelines currently in development under
the umbrella of the Swiss society for infectious diseases.
Many AMS activities – such as antimicrobial formulary re-
strictions and approval systems, review of antimicrobial
prescriptions with point of care intervention, and direct
feedback or therapeutic drug monitoring – are currently
lacking in the majority of Swiss hospitals surveyed. Devel-
opment of a modular formal AMS standard for Swiss hos-
pitals may aid in advancing current AMS strategies and in
introducing AMS programmes in Switzerland. In combina-
tion with the surveillance of antimicrobial use and resis-
tance by ANRESIS, the national antimicrobial resistance
surveillance system, this approach may reduce the use of
antimicrobial agents and consequently the risk of emer-
gence of multi-resistant pathogens.
Key words: antimicrobial stewardship, antibiotic resis-
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Introduction
Antimicrobial resistance is a growing global health prob-
lem that threatens public health throughout the world as
acknowledged by the 2014 World Health Organization
(WHO) report on antimicrobial resistance [1]. This is par-
ticularly true for infections with multi-drug-resistant gram-
negative bacteria, which are associated with a significantly
elevated mortality risk [2, 3] and economic burden [4].
In addition, the World Bank considers antimicrobial resis-
tance to cause global economic damage on a par with the
2008 financial crisis [5]. According to the Swiss surveil-
lance system (www.anresis.ch), resistance of Escherichia
coli and Klebsiella pneumoniae to third or fourth genera-
tion cephalosporins has increased continuously during the
last ten years. Strategies to address this problem include es-
tablishing a comprehensive surveillance system for antimi-
crobial resistance and usage of an effective antimicrobial
stewardship (AMS) system; improving infection preven-
tion and control measures; investing in the development of
new antibiotics; and increasing awareness and understand-
ing of antimicrobial resistance.
AMS is a collection of strategies and tools to improve clin-
ical outcomes and the use of antimicrobials by promoting
the selection of the optimal antimicrobial regimen, dose,
duration and route of administration. It is considered a key
strategy in local and national programmes to prevent the
emergence of antimicrobial resistance. Successful AMS
programmes have demonstrated a significant reduction in
overall and inappropriate antimicrobial use and may also
impact on antimicrobial resistance and clinical outcomes
[6–8]. However, comprehensive future studies are required
to judge the impact of AMS programmes on cost effec-
tiveness [9] and major health outcomes. A recent meta-
analysis documented a significant association of AMS pro-
grammes with a reduced incidence of Clostridium difficile
infection, the most common nosocomial pathogens in pa-
tients with diarrhoea [10]. Many hospitals around the
world still lack AMS programmes, primarily because of a
lack of personnel and funding [11], which may be true for
Switzerland, too.
In 2013, the heads of the Swiss Federal Department of
Home Affairs and the Federal Department of Economic
Affairs, Education and Research commissioned the Fed-
eral Offices for Health (FOPH), Food Safety and Veteri-
nary Affairs (FSVO), Agriculture (FOAG) and the Envi-
ronment (FOEN) to draw up a comprehensive antibiotic
strategy for Switzerland (StAR). Appropriate use of antibi-
otics has been defined as one of eight strategic objectives
directed towards achieving the primary objective of ensur-
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ing the long-term efficacy of antibiotics in preserving hu-
man and animal health. This also includes developing na-
tional AMS guidelines and toolkits for use in hospitals and
outpatient services. However, data on the prevalence of ex-
isting AMS programmes or local strategies to improve an-
timicrobial prescription in Switzerland are lacking.
The aim of the current survey was to perform an in-depth
review describing AMS activities currently being under-
taken in Swiss hospitals to elucidate specific gaps and
to identify potential future aspects of AMS strategies in
Switzerland.
Methods
The survey was developed by the authors following a re-
view of the literature and previous AMS surveys [11, 12].
A web-based survey tool (SurveyMonkey®) was used. In
December 2016, a letter of invitation stating the purpose
of the survey was sent to qualified senior staff members
at Swiss hospitals including infectious diseases physicians
and members of Swissnoso (primary choice, whenever
possible), internal medicine physicians, or other senior
staff members. A total of 134 Swiss hospitals offering
overnight stays to patients were included, with mental
health facilities being excluded due to low levels of an-
timicrobial prescription. The original three-week collec-
tion period was extended to two months to maximise the
response rate and included direct contact of the respective
senior staff member via telephone. The survey (appendix
1, available in a separate file for downloading) consisted
of 53 questions, which were mainly closed questions with
the option of a free-text response. Only one respondent
per hospital was allowed, but the survey could be accessed
again to complete all required information. Only entries
with 50% or more of the questions answered were included
in the analysis. Non-respondents were reminded by tele-
phone or email at least twice.
Key findings of the survey
Sixty-nine of the134 eligible hospitals survey responses
were returned. Six entries had to be excluded (>50% miss-
ing data). Hence, a total of 63/134 (47%) hospitals or hos-
pital networks (n = 3 with a total of 11 hospitals) com-
pleted the questionnaire. University and cantonal hospitals
accounted for 26/63 (41%) of the returns (response rate
74%), regional hospitals for 23/63 (37%) (response rate
51%), and private or rehabilitation hospitals for 14/63
(22%) (response rate 26%). The survey was mainly an-
swered by infectious diseases (65%) or internal medicine
physicians (25%). Hospitals with up to 200 beds accounted
for 35/63 (55%), those with 201 to 500 beds for 18/63
(29%) and those with over 500 beds for 10/63 (16%) of the
total. Intensive or intermediate care unit beds were avail-
able in all but 5 hospitals (median 10 (range 2–100) beds).
Availability of resources and AMS structure
Infectious diseases physicians, clinical microbiologists,
and ward pharmacists were available on site in 49/63
(79%), 27/63 (43%), and 25/63 (40%) of hospitals with
none of these resources available in 10/63 (16%) of hos-
pitals. Whereas the majority of hospitals reported the ex-
istence of a drug and therapeutics committee (67%), AMS
committees were only present in 21% of hospitals. Similar-
ly, a published AMS strategy and policy were only report-
ed by 21/63 (33%) and14/63 (22%) of hospitals respec-
tively. Infectious diseases physicians were responsible for
improving and evaluating antimicrobial use in many hos-
pitals (71% and 60%, respectively), whereas pharmacists
were involved less frequently (13% and 24%, respective-
ly). Overall, an official AMS programme was implemented
in only 18/63 (29%) of hospitals (3 university, 6 cantonal,
5 regional and 4 private hospitals) for a median duration
of 6 years (range 1–15), and a median of 3 hours (range
1–20) of dedicated resources per week were available for
this programme.
Hospital-specific antimicrobial treatment recommenda-
tions were available in the majority of hospitals (79%) in-
cluding the use of guidelines from tertiary hospitals (6%).
Most treatment guidelines had been updated within the
previous 2 years (87% of all guidelines). Topics covered
in the majority (>50%) of guidelines were avoidance of
broad-spectrum antimicrobials (70%), specimen collection
(62%), duration of treatment (74%), intravenous to oral
switch (60%), treatment recommendation for specific indi-
cations (76%), surgical antibiotic prophylaxis (74%), dos-
ing for special populations (e.g., renal impairment, 50%),
and alternative antimicrobial choices (e.g., if allergic,
64%). In contrast, guidelines less frequently (<50%) con-
tained information regarding antibiotic formulary (includ-
ing restricted antibiotics), review of antimicrobial therapy
after 48–72 hours, therapeutic drug monitoring, antifungal/
antiviral treatment, side effects, outpatient parenteral an-
timicrobial therapy, and emphasis on documenting the in-
dications of antimicrobial treatment (table 1). 48/63 (76%)
and 37/63 (59%) of respondents respectively reported that
antimicrobial resistance and rates of infection with
Clostridium difficile were monitored at their institution.
Objectives of and barriers to a comprehensive AMS
programme
With regards to the three key objectives of a current or
planned AMS programme, reduction of antimicrobial re-
Table 1: Topics covered in antimicrobial treatment guidelines or stew-
ardship policy according to the respondents surveyed (n = 50; guide-
lines were not available in 13 hospitals).
Topic Percentage
Avoidance of broad-spectrum antimicrobials 70%
Documentation of indications and severity of illness 30%
Specimen collection before antimicrobial treatment
initiation
62%
Treatment duration 74%
Antibiotic formulary 36%
Review of antibiotic therapy at 48 to 72 hours 42%
Intravenous to oral switch 60%
Therapeutic drug monitoring 38%
Treatment of specific diseases 76%
Situations when antimicrobial therapy is NOT re-
quired
48%
Antifungal treatment 46%
Antiviral treatment 32%
Surgical antibiotic prophylaxis 74%
Alternative antimicrobial choices (e.g., if allergic) 64%
Dosage for special populations (e.g., renal impair-
ment)
50%
Side effects 16%
Outpatient parenteral antibiotic therapy 12%
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sistance (39/63, 62%), reduction of the use of antimicrobial
drugs (34/63, 54%) and improvement of antimicrobial pre-
scription (27/63, 43%) were cited most frequently. In con-
trast, reduction of C. difficile infections and costs were per-
ceived as the least important goals (5/63, 8% and 9/63,
14%, respectively).
Barriers to successful implementation of an effective AMS
programme were identified in 47/63 (75%) of hospitals, in
particular with regards to lack of personnel or funding (44/
63, 70% and 27/63, 43%, respectively), which was most
commonly described in university/cantonal and regional
hospitals. A further 20/63 (32%) perceived prescriber op-
position as a relevant barrier to a comprehensive AMS,
particularly in private hospitals (6/14 (43%). Appropriate
resources (financial, manpower, IT support), the establish-
ment of a multidisciplinary AMS teams, and support from
hospital administration services were identified as the most
important requirements for an effective AMS programme
(51/63 (84%), 41/63 (67%), and 40/63 (66%), respective-
ly) followed by the availability of hospital-specific antimi-
crobial resistance and antimicrobial usage data and of an
antimicrobial prescription policy. The availability of elec-
tronic prescription and the implementation of national re-
porting and benchmarking of antimicrobial use and pre-
scription quality were perceived as less important (<33%).
Hospitals were asked about core and optional elements of
future Swiss AMS programmes (table 2). Implementation
of national or in-house clinical treatment guidelines, edu-
cation of prescribers about good antimicrobial prescription
practice, monitoring of hospital-specific antimicrobial re-
sistance, and active surveillance of positive blood cultures
with direct feedback were perceived as core elements by
the majority of hospitals (>75%). Additionally, implemen-
tation of national or in-house diagnostic evaluation guide-
lines, review of antimicrobial prescription with immediate
feedback, and hospital-specific antibiograms were regard-
ed as core elements by at least 50% of respondents. The
most frequent optional elements were use of rapid diagnos-
tic tests with or without stewardship advice, the use of pro-
calcitonin to decrease antibiotic treatment duration, point
prevalence surveys of the quality of antimicrobial prescrip-
tion, selective reporting of susceptibility testing, therapeu-
tic drug monitoring with stewardship advice, establishment
of diagnostic pathways for patients with reported β-lactam
antibiotic allergy, and the use of information technology
such as clinical decision support or online approval sys-
tems (all >50%). With regard to local limitations, only the
use of procalcitonin to decrease antibiotic treatment du-
ration and of antimicrobial formulary restriction and ap-
proval systems were most commonly cited as not feasible
by the surveyed hospitals (12/63, 19%, and 11/63, 17%).
Almost all respondents agreed that their patients would
benefit from an AMS programme (60/63, 95%) and that a
national AMS strategy including compulsory and optional
stewardship elements would be desirable (53/63, 84%).
Education
Overall, the majority of respondents indicated that they
provide education to hospital staff on antimicrobial re-
sistance and on improving antimicrobial prescription
(90%).This included senior and junior medical staff (78%
and 84%, respectively), but rarely nurses or pharmacists
(19% and 2%, respectively). Face-to-face training was the
mode primarily used in the majority of hospitals (76%),
with short education courses or written information provid-
ed less frequently (49% and 27%, respectively).
AMS activities and strategies
Various strategies were employed by the hospitals sur-
veyed. Whereas most hospitals had a defined formulary of
antimicrobial agents (43/63 (68%)), restrictions on the use
of selected and/or broad-spectrum antimicrobials were in-
frequently implemented (18/63 (29%)), which mainly in-
cluded carbapenems (56%), daptomycin and/or linezolid
(44%), antifungal drugs excluding fluconazole (56%) and
rarely vancomycin, quinolones and cephalosporins (17%,
17% and 11%, respectively). Infectious diseases physi-
cians were mainly involved in the approval process (72%).
AMS ward rounds existed in a minority of surveyed hospi-
tals (9/63 (14%)) and were mainly conducted in the inten-
sive care unit. Similarly, review of antimicrobial prescrip-
tions with point-of-care intervention and direct feedback
was employed infrequently (14/63 (23%)) with a medi-
an of 2 hours spent per week and almost exclusively per-
formed by infectious diseases specialists (92%). Respon-
dents indicated that these sessions mainly included the re-
view of indications and compliance with policy/guidelines,
appropriateness of dose, route and duration, treatment ac-
cording to culture results, and de-escalation possibilities
Table 2: Core and optional elements that an antimicrobial stewardship programme in Swiss hospitals should consist of according to the respondents surveyed (n = 63).
Antimicrobial stewardship element Core/compulsory Optional Not feasible
Antimicrobial treatment guidelines 90.5% 7.9% 1.6%
Diagnostic evaluation guidelines 54.0% 44.4% 1.6%
Antimicrobial formulary restriction and approval systems 38.1% 46.0% 15.9%
AMS ward rounds with intervention 52.4% 38.1% 9.5%
Monitoring of prescription performance with feedback to prescribers 31.8% 55.6% 12.7%
Monitoring of hospital-specific antimicrobial resistance 84.1% 14.3% 1.6%
Selective reporting of susceptibility testing 46.0% 50.8% 3.2%
Education of prescribers about good antimicrobial prescribing practice and resistance 87.3% 12.7% 0%
Clinical decision-support systems 19.1% 63.5% 17.5%
Annual publication of hospital-specific antibiograms 58.7% 36.5% 3.2%
Therapeutic drug monitoring with stewardship advice 27.0% 61.9% 11.1%
Use of rapid diagnostic tests with/without stewardship advice 27.0% 65.1% 7.9%
Active surveillance of positive blood cultures 74.6% 23.8% 1.6%
Diagnostic pathway for patients with reported beta-lactam allergy 38.1% 57.1% 4.8%
Use of procalcitonin to decrease treatment duration 14.3% 66.7% 19.1%
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(all 100%), whereas IV to oral switch and therapeutic drug
monitoring were evaluated less frequently (79%).
Additional AMS interventions and strategies were em-
ployed infrequently (table 3) in the majority of hospitals
with the exception of routine follow-up of patients with
positive blood cultures and the monitoring of Staphylococ-
cus aureus or Candida spp. bloodstream infection. In par-
ticular, interventions to reduce the duration of antibiotic
treatment including procalcitonin testing, automatic stop/
review orders including a recommendation to review the
appropriateness of all antimicrobials within 48 to 72 hours,
alerts or criteria for IV to oral switch, and alerts for dose
adjustment in case of organ dysfunction were utilised
rarely.
Cumulative antibiograms provided by internal or external
microbiological laboratories were available in the majority
of hospitals surveyed (38/63 (60%)). However, access to
these antibiograms was limited to infectious disease physi-
cians or infection-control nurses in a considerable number
of hospitals (27%). Some physicians indicated that their
microbiological laboratory would use selective reporting
of susceptibility data for all areas (24/62 (39%)).
Evaluation of AMS programmes, strategies and inter-
ventions
Antimicrobial consumption at the hospital level was moni-
tored by 15/63 (24%) of hospitals and even less so at ward
or department level (5/63, 8% and 7/63, 11%). Antimicro-
bial costs and data on consumption of specific antimicro-
bials were assessed by only 7/63 (11%) of hospitals.
Formal antimicrobial audits were conducted in 33/63
(52%) of hospitals (table 4). The most frequently undertak-
en audits were compliance with surgical antibiotic prophy-
laxis (27/33, 82%), microbiological cultures taken before
start of antimicrobial treatment (9/33, 27%), and therapeu-
tic drug monitoring for vancomycin and/or aminoglyco-
sides (5/33, 15%). Documentation of indication, time to
first dose in sepsis, adherence to treatment guidelines, du-
ration of antimicrobial therapy, IV to oral switch, de-esca-
lation/adaption of antimicrobial therapy after 48–72 hours
or audits of specific clinical conditions (e.g., community-
acquired pneumonia) were carried out infrequently (<10%)
or not at all. Many respondents quoted that practice related
to antimicrobial prescription and management was never
audited (30/63, 48%), and even in hospitals with formal
antimicrobial audits, only a minority of audits suggested
in the literature were performed. More than two different
audits were undertaken in only a single surveyed hospital.
The results of the respective audits were reported to pre-
scribers in a minority of hospitals conducting formal an-
timicrobial audits (15/33, 45%).
Discussion
The present survey is the first to describe existing AMS
strategies and activities in Switzerland, including the de-
sired aims of a future AMS programme and barriers to its
implementation. Overall, the presence of a comprehensive
AMS programme, including the presence of an AMS com-
mittee, policy, audits and guidelines, is unusual in Switzer-
land. Instead, individual standalone AMS strategies are
being implemented in the majority of hospitals. These in-
clude the use of treatment guidelines and monitoring of
positive blood cultures with direct feedback.
The most obvious differences as compared to results from
a worldwide survey of 660 hospitals [11] and a survey
from Victoria/Australia [12] are the following:
AMS activities are less structured in Swiss hospitals com-
pared with other settings. Whereas AMS programmes were
reported in 56% of worldwide hospitals, this was only true
Table 4: Antimicrobial audits conducted at the hospitals surveyed (n =
63).
Topic Percentage
Time to first dose in sepsis 3.2%
Surgical antibiotic prophylaxis 43.6%
Microbiological specimen taken before starting an-
timicrobial therapy
14.5%
Adherence to treatment guidelines 4.8%
De-escalation of antimicrobial therapy within 48–72
hours
0%
Duration of antimicrobial therapy 3.2%
Intravenous to oral switch 4.8%
Use of therapeutic drug monitoring for vancomycin
and/or aminoglycosides
8.1%
Audit of specific antimicrobials 3.2%
Audit of restricted antimicrobials 3.2%
Audit of specific units/wards 6.5%
None 48.3%
Table 3: Antimicrobial stewardship interventions implemented in the hospitals surveyed (n = 62; answers from one single hospital missing).
Antimicrobial stewardship intervention In all areas In some areas Not implemented
Selective reporting of antimicrobial susceptibilities 38.7% 14.5% 46.8%
Automatic stop/review orders 8.1% 3.2% 88.7%
Dose adjustment alerts in case of organ dysfunction 6.5% 8.1% 85.5%
Intravenous to oral switch alerts or criteria 9.7% 6.5% 83.9%
Therapeutic drug monitoring alerts 14.5% 8.1% 77.4%
Surveillance of positive blood cultures with feedback 58.1% 8.1% 33.9%
Surveillance of S. aureus and/or Candida spp. Bloodstream infection with active involve-
ment
45.2% 3.2% 51.6%
Policy to review all antibiotics after 48 to 72 hours 21.0% 8.1% 71.0%
Review of selected antimicrobial agents with feedback 14.5% 4.8% 80.6%
Procalcitonin testing to prevent initiation of antimicrobials 12.9% 22.6% 64.5%
Procalcitonin testing to stop antimicrobials 8.1% 21.0% 71.0%
Clinical decision-support systems 3.2% 0% 96.8%
Interventions for specific infections 30.7% 12.9% 56.5%
Interventions to reduce duration of antimicrobial treatment 25.8% 9.7% 64.5%
Use of procalcitonin to decrease treatment duration 14.3% 66.7% 19.1%
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in 29% of the Swiss hospitals surveyed. With the exception
of implementation of treatment guidelines and monitoring
of bloodstream infections, the majority of recognised AMS
strategies were considerably under-utilised in Swiss hos-
pitals. For example, restrictions on the use of broad-spec-
trum antimicrobial drugs and AMS ward rounds with di-
rect feedback to the prescriber were only present in 29%
and 14% of hospitals surveyed respectively, in contrast to
84% and 64% of worldwide and 30% and 52% of hospi-
tals in Victoria. Interventions to reduce treatment duration
and automatic stop/review orders were rarely employed,
as were selective reporting of susceptibility data (39% vs
93% in hospitals in Victoria). Similarly, evaluation of an-
timicrobial use is conducted less frequently in the Swiss
hospitals surveyed (52% vs 80% of worldwide hospitals
and 47% of hospitals in Victoria) with the exception of
compliance with surgical antibiotic prophylaxis. In partic-
ular, documentation of indications, adherence to treatment
guidelines, and duration of antimicrobial treatment were
routinely evaluated in less than 10% of Swiss hospitals sur-
veyed. Overall, antimicrobial consumption was monitored
in 22% of Swiss hospitals compared to 85% of worldwide
hospitals.
In Australia, the Australian Commission on Safety and
Quality in Health Care has defined five essential strategies
for an effective AMS programme [13]. When assessing the
results of the present survey against these strategies (fig.
1), it is clear that considerable gaps exist in most hospi-
tals with regard to the implementation of an AMS pro-
gramme (with the exception of the implementation of treat-
ment guidelines). The same result is evident when using
the Core Elements of Hospital Antibiotic Stewardship Pro-
grammes of the Centers for Disease Control and Preven-
tion as the comparator [14]. As expected, AMS strategies
were most frequently implemented in university hospitals,
whereas the opposite was true for private hospitals. This
was particularly the case for the establishment of formula-
ry restrictions and approval systems (57% and 8% in uni-
versity and private hospitals respectively) and the imple-
mentation of antimicrobial treatment guidelines (100% and
69% respectively).
In line with hospitals around the globe, education on AMS
was provided in the majority of Swiss hospitals, mainly
in a face-to-face manner. In addition, lack of personnel or
Figure 1: Presence of the five essential antimicrobial stewardship
strategies (as defined by the Australian Commission on Safety and
Quality in Health Care) in Swiss hospitals surveyed (n = 63).
funding and prescriber opposition were perceived as the
main barriers by survey respondents.
Respondents were also queried about their vision for ele-
ments and aims for a future Swiss AMS programme. Al-
though lack of funding and personnel followed by pre-
scriber opposition, in other words potentially major ad-
ministrative/managerial challenges, were perceived as the
main barriers to AMS implementation, almost all respon-
dents thought that a national AMS strategy including com-
pulsory and optional stewardship elements would be de-
sirable (53/63, 84%) and that AMS programmes are of
benefit for patients (95%). The Joint Commission for Ac-
creditation of hospitals, an independent, not-for-profit or-
ganisation of the United States, has set requirements for
AMS that, to our knowledge, have not been met in a single
Swiss hospital [15]. The most frequently cited goal of any
future AMS programme was reduction of antimicrobial re-
sistance followed by reduction in the overall use of an-
timicrobials, even when limited data are available to sup-
port the view of the respondents. Implementation of treat-
ment guidelines, active surveillance of positive blood cul-
tures, monitoring of hospital-specific antimicrobial resis-
tance and education of prescribers about good antimicro-
bial prescription practice were perceived as core elements
of a future AMS programme in Switzerland, which is not
surprising as these elements are already established in the
majority of hospitals surveyed. Other important AMS
strategies such as point prevalence survey of quality of
antimicrobial prescription, selective reporting of suscep-
tibility testing, and the use of clinical decision or online
approval systems were mainly regarded as optional ele-
ments. Interestingly, restriction of certain antimicrobials
combined with approval systems was most commonly cit-
ed as not feasible. This is a strategy that is regarded as es-
sential in some countries.
Our survey has several limitations. First, the response rate
of only 47% was low, which limits the validity of our sur-
vey results. Whereas all university hospitals and the ma-
jority of cantonal hospitals responded, many private, re-
gional and rehabilitation hospitals, which may have limited
resources for AMS, did not participate. Hence, our survey
provides insight into current and future AMS activities and
requirements of mainly larger hospitals. Second, a com-
prehensive validation of data entry was not feasible. Al-
though our intent was to select respondents with the most
comprehensive overview of AMS strategies employed in
a hospital and who are familiar with the AMS terminol-
ogy, the interpretation of definitions used in the survey
may still differ significantly. Third, our results regarding
AMS programmes, strategies and activities may represent
an overestimation of the true prevalence owing to signifi-
cant non-response bias (mainly of private, regional and re-
habilitation hospitals) and the inclusion of mainly infec-
tious diseases physicians who may overestimate their AMS
activities. On the other hand, this survey may also underes-
timate currently implemented AMS strategies, as pharma-
cists, who play a crucial role in delivering AMS activities
in many countries and maybe also in Switzerland, were not
surveyed. On May 9, 2017, Swissnoso organised a kick-
off meeting for a Swiss national AMS with stakeholders
including hospital pharmacists and insurance representa-
tives, the Swiss medical association (FMH), the Swiss hos-
pital association (H+) and others to gain as much input as
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possible with a view to launching AMS in Switzerland. For
2017 several activities are planned including on-site vis-
its to different hospitals, development of monitoring strate-
gies (antibiotic consumption and resistance) and identifica-
tion of AMS strategies, and interventions with a significant
impact and a realistic chance of successful (in terms of re-
sources required) implementation in different Swiss hospi-
tals.
In conclusion, Swiss hospitals are at different stages of
implementing AMS strategies. Comprehensive AMS pro-
grammes are unusual, which may be related to a lack of
funding and personnel, given that the overwhelming ma-
jority of respondents favour AMS programmes to reduce
antimicrobial resistance and the use of antimicrobial drugs.
The establishment of modular national AMS standards or
guidelines may aid in advancing current AMS strategies
and introduce AMS programmes in Swiss hospitals, while
at the same time offering flexibility to account for local
healthcare structure and resources.
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Appendix 1 Antimicrobial Stewardship Questionnaire
The questionnaire is available as a separate file at:
https://smw.ch/en/article/doi/smw.2017.14512/
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